Gilead Sciences, Inc.
—- Market cap
- $179.56B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $179.56B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: GILD stock price near parity vs BMY $144.81 current versus $124.92 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMY's multiple
Implied fair value · at GILD's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 74% equity / 26% debt · EV / Revenue 3.43x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$59.11
Base
$72.93
Bull
$92.88
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GILD can sustain its stronger margin structure and modest growth while keeping leverage contained, then hold or accumulate on weakness because the stock’s premium-quality fundamentals are already reflected in a price that is only modestly below the P/E-implied value.
GILD’s current price of $130.21 is only 1.7% above the P/E-implied value of $127.98, so the market is already close to the multiple-based estimate. The stock looks inexpensive versus its historical band top-end but expensive relative to the DCF range, while BMY-implied value spans a very wide range.
Supporting Metrics